Ryvu Therapeutics SA
WSE:RVU
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
39.7
64.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ryvu Therapeutics SA
Long-Term Debt
Ryvu Therapeutics SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Long-Term Debt
zł80.6m
|
CAGR 3-Years
198%
|
CAGR 5-Years
47%
|
CAGR 10-Years
66%
|
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Long-Term Debt
zł0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Long-Term Debt
zł0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Selvita SA
WSE:SLV
|
Long-Term Debt
zł180.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ryvu Therapeutics SA
Glance View
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
See Also
What is Ryvu Therapeutics SA's Long-Term Debt?
Long-Term Debt
80.6m
PLN
Based on the financial report for Sep 30, 2024, Ryvu Therapeutics SA's Long-Term Debt amounts to 80.6m PLN.
What is Ryvu Therapeutics SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
66%
Over the last year, the Long-Term Debt growth was 18 858%. The average annual Long-Term Debt growth rates for Ryvu Therapeutics SA have been 198% over the past three years , 47% over the past five years , and 66% over the past ten years .
You don't have any saved screeners yet
